期刊
CURRENT OPINION IN IMMUNOLOGY
卷 51, 期 -, 页码 55-61出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2018.02.004
关键词
-
类别
资金
- National Institute of Health [R01CA 208246, R01CA204021]
- DOD USARMC [W81NWH150406]
NKG2D is an activating immune receptor expressed by NK and effector T cells. Induced expression of NKG2D ligand on tumor cell surface during oncogenic insults renders cancer cells susceptible to immune destruction. In advanced human cancers, tumor cells shed NKG2D ligand to produce an immune soluble form as a means of immune evasion. Soluble NKG2D ligands have been associated with poor clinical prognosis in cancer patients. Harnessing NKG2D pathway is considered a viable avenue in cancer immunotherapy over recent years. In this review, we will discuss the progress and perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据